Leaders in bioelectronic research and product development, NuroKor launches firest equine bioelectronic therapy system into US market
NuroKor Bioelectronics, a world-leading bioelectronics company, has launched the first equine bioelectronic therapy system into the US market. The EquiPod offers US horse owners and equestrian professionals access to app-controlled tech specially designed to accelerate their horses’ recovery, manage pain and optimise performance.
Addressing the national equine health emergency
Musculoskeletal, lower limb injuries and wounds are one of the main reasons for veterinary visits for all horses and across all levels of equestrian sport in the US. The US equine healthcare market was valued at around $919.6m in 2021, with around 10.5m horses in America. Prolonged injury is expensive for owners and uncomfortable for horses. However, few affordable and effective treatment options exist to prevent the horses’ suffering and accelerate their return to full fitness.
Bringing the therapeutic potential of equine bioelectronics to the US
The first and only app-controlled therapeutic to launch into this market, NuroKor’s EquiPod provides a range of treatment programmes suitable for injured and healthy horses across all ages and levels of performance. This lightweight therapeutic system delivers a non-invasive microcurrent to target joints and soft tissues. These regulate or elicit physiological responses known to support or enhance a wide range of physiological repair and recovery processes.
Built based on insights from 3 years of R&D and 2 years of testing, EquiPod offers three programmes:
- Repair and recovery, which supports physical recovery and aids healing for wounds and injuries.
- Pain management, for the effective and drug-free management of chronic and acute pain.
- Maintenance and wellbeing, which aims to promote physical health and functional well-being of joints and soft tissues.
A pivotal stage in NuroKor’s global expansion
NuroKor Bioelectronics was founded by veteran medical device entrepreneur Rick Rowan, the organisation has already successfully scaled bioelectronic solutions in the human physical therapy and pain management sectors. The launch of their EquiPod product range into the US market is a major milestone in the company’s international expansion and will be followed up by launches into European and Asian markets over the next 12 months. The product is already available in the United Kingdom.
